We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Tir7.8
Tirzepatide Research
Mostly mechanism / observational
108 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Tirzepatide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 1,995 participants.
Based on 108 studies · 39 meta-analyses · 54 RCTs · 730,976 total participants
Confidence
High confidence
By outcome
Weight managementMean weight reductions up to ~21% over 72 weeks in obesity trials — the largest of any approved weight-loss drug to date, superior to semaglutide head-to-head · Months (dose-escalated over ~20 weeks)
Mostly mechanism / observational70 studies
Glycemic & metabolic controlLowers HbA1c by roughly 1.9-2.6 percentage points in phase-3 diabetes trials; superior to basal insulin and semaglutide 1 mg head-to-head · Weeks to months · Combined large weight loss and strong glycemic control improve overall metabolic status · Months
Mostly mechanism / observational42 studies
Heart & blood pressure
Mostly mechanism / observational19 studies
Safety profile
Mostly mechanism / observational15 studies
Sleep apnea & respiratory
Too few graded studies2 studies
Active research area
108 studies in the last 5 years · Latest meta-analysis: 2026
20212026
1Meta-Analysisn=7,111 · very large study2025
Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, Salvador Oscco EL, Patiño Araujo B, Banda S, Escobar Liquitay CM, Bracchiglione J, Meza N, Madrid E. · The Cochrane database of systematic reviews (2025)
Tirzepatide may result in an increase in non-serious adverse events (RR 1.33, 95% CI 1.03 to 1.71; 5 studies, 4582 participants; low-certainty evidence).
The evidence is very uncertain about the effect on serious adverse events (RR 0.99, 95% CI 0.88 to 1.12; 8 studies, 6359 participants; very low-certainty evidence).
Tirzepatide may result in little to no difference in adverse events leading to withdrawal (RR 2.06, 95% CI 1.21 to 3.52; 8 studies, 6359 participants; low-certainty evidence).
In plain English: Further prospective trials are needed to clarify causal mechanisms and inform clinical decision-making.
Liang CS et al. · International journal of molecular sciences (2026)
Odds ratios (ORs) with 95% credible intervals (CrIs) were calculated, and surface under the cumulative ranking curves (SUCRA) were used to estimate relative safety rankings.
Only high-dose tirzepatide (10-15 mg/week) was associated with a significantly increased risk of AKI compared to controls (absolute risk difference: 0.28%; number needed to harm: 357).